Jean M. Tersak
Experienced in Alveolar Soft Part Sarcoma
Experienced in Alveolar Soft Part Sarcoma
4401 Penn Avenue, 
Pittsburgh, PA 

Overview

Jean M. Tersak, MD, provides care for pediatric oncology patients and long term survivors of childhood cancer at UPMC Children’s Hospital of Pittsburgh. Dr. Tersak is institutional principal investigator for the UPMC Children’s Oncology Group and director of clinical oncology research within the Division of Pediatric Hematology/Oncology. She is also a professor of pediatrics and clinical and translational science at the University of Pittsburgh School of Medicine and is board-certified in pediatric hematology/oncology. Dr. Tersak earned her bachelor's degree, master’s degree, and  medical degree from the University of Pittsburgh. She completed her residency and fellowship at UPMC Children’s Hospital of Pittsburgh. Dr. Tersak is extensively involved in clinical research including the evaluation and treatment of patients with new diagnosis. Her research interests include the late effects, quality of life, and neurocognitive outcomes in survivors of childhood cancer and evaluation and treatment of opsoclonus myoclonus in patients with neuroblastoma. She is a member of the American Society of Clinical Oncology Children’s Oncology Group. View the full list of Dr. Tersak’s publications on PubMed.

Dr. Tersak is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Neuroepithelioma, Neuroblastoma, Histiocytosis, Bone Marrow Aspiration, and Splenectomy.

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 62 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Alveolar Soft Part Sarcoma.

Graduate Institution
University Of Pittsburgh School Of Medicine
Residency
University of Pittsburgh School of Medicine
Specialties
Pediatric Hematology Oncology
Licenses
Specialist in PA
Board Certifications
American Board Of Pediatrics
Fellowships
University of Pittsburgh School of Medicine
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 7 Less Insurance Carriers -

Locations

Pediatric Hematology Oncology in Lawrenceville
4401 Penn Avenue, Pittsburgh, PA 15224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


60 Clinical Trials

A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Key Adverse Events After Childhood Cancer
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
View 49 Less Clinical Trials

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tersak's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 27 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile